ICECURE MEDICAL LTD (ICCM) Fundamental Analysis & Valuation

NASDAQ:ICCM • IL0011224156

Current stock price

0.33 USD
+0.03 (+9.38%)
At close:
0.3122 USD
-0.02 (-5.39%)
After Hours:

This ICCM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ICCM Profitability Analysis

1.1 Basic Checks

  • In the past year ICCM has reported negative net income.
  • In the past year ICCM has reported a negative cash flow from operations.
  • In the past 5 years ICCM always reported negative net income.
  • ICCM had a negative operating cash flow in each of the past 5 years.
ICCM Yearly Net Income VS EBIT VS OCF VS FCFICCM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M

1.2 Ratios

  • ICCM's Return On Assets of -108.42% is on the low side compared to the rest of the industry. ICCM is outperformed by 83.51% of its industry peers.
  • Looking at the Return On Equity, with a value of -166.36%, ICCM is doing worse than 73.40% of the companies in the same industry.
Industry RankSector Rank
ROA -108.42%
ROE -166.36%
ROIC N/A
ROA(3y)-106.5%
ROA(5y)-81.28%
ROE(3y)-169.6%
ROE(5y)-122.46%
ROIC(3y)N/A
ROIC(5y)N/A
ICCM Yearly ROA, ROE, ROICICCM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 600 800 1K

1.3 Margins

  • ICCM has a worse Gross Margin (36.28%) than 71.28% of its industry peers.
  • ICCM's Gross Margin has declined in the last couple of years.
  • ICCM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 36.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.22%
GM growth 5Y-10.46%
ICCM Yearly Profit, Operating, Gross MarginsICCM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. ICCM Health Analysis

2.1 Basic Checks

  • ICCM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ICCM has been increased compared to 1 year ago.
  • The number of shares outstanding for ICCM has been increased compared to 5 years ago.
  • ICCM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ICCM Yearly Shares OutstandingICCM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
ICCM Yearly Total Debt VS Total AssetsICCM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of -12.23, we must say that ICCM is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -12.23, ICCM is not doing good in the industry: 83.51% of the companies in the same industry are doing better.
  • There is no outstanding debt for ICCM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.23
ROIC/WACCN/A
WACC8.53%
ICCM Yearly LT Debt VS Equity VS FCFICCM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M

2.3 Liquidity

  • ICCM has a Current Ratio of 2.61. This indicates that ICCM is financially healthy and has no problem in meeting its short term obligations.
  • ICCM has a Current ratio (2.61) which is comparable to the rest of the industry.
  • ICCM has a Quick Ratio of 2.07. This indicates that ICCM is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of ICCM (2.07) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.61
Quick Ratio 2.07
ICCM Yearly Current Assets VS Current LiabilitesICCM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. ICCM Growth Analysis

3.1 Past

  • ICCM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.67%, which is quite good.
  • The Revenue has been growing slightly by 2.67% in the past year.
  • ICCM shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.68% yearly.
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
Revenue 1Y (TTM)2.67%
Revenue growth 3Y3.03%
Revenue growth 5Y-2.68%
Sales Q2Q%46.17%

3.2 Future

  • Based on estimates for the next years, ICCM will show a very strong growth in Earnings Per Share. The EPS will grow by 27.63% on average per year.
  • The Revenue is expected to grow by 94.25% on average over the next years. This is a very strong growth
EPS Next Y40.84%
EPS Next 2Y30.94%
EPS Next 3Y34.79%
EPS Next 5Y27.63%
Revenue Next Year105.15%
Revenue Next 2Y89.83%
Revenue Next 3Y105.77%
Revenue Next 5Y94.25%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ICCM Yearly Revenue VS EstimatesICCM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 50M 100M
ICCM Yearly EPS VS EstimatesICCM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 0.2 -0.2 0.4 -0.4

More info and screens

Find the best growth stocksShow best growing peers

1

4. ICCM Valuation Analysis

4.1 Price/Earnings Ratio

  • ICCM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ICCM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ICCM Price Earnings VS Forward Price EarningsICCM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ICCM Per share dataICCM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ICCM's earnings are expected to grow with 34.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.94%
EPS Next 3Y34.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ICCM Dividend Analysis

5.1 Amount

  • No dividends for ICCM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ICCM Fundamentals: All Metrics, Ratios and Statistics

ICECURE MEDICAL LTD

NASDAQ:ICCM (4/7/2026, 5:48:26 PM)

After market: 0.3122 -0.02 (-5.39%)

0.33

+0.03 (+9.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-17
Earnings (Next)05-06
Inst Owners0.76%
Inst Owner Change0%
Ins Owners40.42%
Ins Owner Change0%
Market Cap22.76M
Revenue(TTM)3.38M
Net Income(TTM)-15.06M
Analysts82.5
Price Target3.11 (842.42%)
Short Float %1.7%
Short Ratio1.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-35.08%
Min EPS beat(2)-52.51%
Max EPS beat(2)-17.65%
EPS beat(4)2
Avg EPS beat(4)-8.54%
Min EPS beat(4)-52.51%
Max EPS beat(4)26.47%
EPS beat(8)4
Avg EPS beat(8)-3.18%
EPS beat(12)8
Avg EPS beat(12)1.19%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-8.65%
Min Revenue beat(2)-34%
Max Revenue beat(2)16.71%
Revenue beat(4)1
Avg Revenue beat(4)-11.21%
Min Revenue beat(4)-34%
Max Revenue beat(4)16.71%
Revenue beat(8)2
Avg Revenue beat(8)-10.32%
Revenue beat(12)3
Avg Revenue beat(12)-14.68%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.4%
PT rev (3m)-2.4%
EPS NQ rev (1m)10%
EPS NQ rev (3m)10%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)61.34%
Revenue NQ rev (3m)61.34%
Revenue NY rev (1m)56.15%
Revenue NY rev (3m)56.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.73
P/FCF N/A
P/OCF N/A
P/B 2.51
P/tB 2.51
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0.05
BVpS0.13
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -108.42%
ROE -166.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 36.28%
FCFM N/A
ROA(3y)-106.5%
ROA(5y)-81.28%
ROE(3y)-169.6%
ROE(5y)-122.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.22%
GM growth 5Y-10.46%
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.2%
Cap/Sales 1.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.61
Quick Ratio 2.07
Altman-Z -12.23
F-Score4
WACC8.53%
ROIC/WACCN/A
Cap/Depr(3y)60.73%
Cap/Depr(5y)189.18%
Cap/Sales(3y)6.03%
Cap/Sales(5y)11.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
EPS Next Y40.84%
EPS Next 2Y30.94%
EPS Next 3Y34.79%
EPS Next 5Y27.63%
Revenue 1Y (TTM)2.67%
Revenue growth 3Y3.03%
Revenue growth 5Y-2.68%
Sales Q2Q%46.17%
Revenue Next Year105.15%
Revenue Next 2Y89.83%
Revenue Next 3Y105.77%
Revenue Next 5Y94.25%
EBIT growth 1Y3.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.01%
OCF growth 3YN/A
OCF growth 5YN/A

ICECURE MEDICAL LTD / ICCM Fundamental Analysis FAQ

What is the fundamental rating for ICCM stock?

ChartMill assigns a fundamental rating of 3 / 10 to ICCM.


What is the valuation status of ICECURE MEDICAL LTD (ICCM) stock?

ChartMill assigns a valuation rating of 1 / 10 to ICECURE MEDICAL LTD (ICCM). This can be considered as Overvalued.


What is the profitability of ICCM stock?

ICECURE MEDICAL LTD (ICCM) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ICECURE MEDICAL LTD?

The Earnings per Share (EPS) of ICECURE MEDICAL LTD (ICCM) is expected to grow by 40.84% in the next year.